Monday June 26th 2017

Archive for November, 2011

Ottawa moving too slow on patient trials for MS treatment, patient believes

Ottawa moving too slow on patient trials for MS treatment, patient believes

Early phase patient trials for the experimental Liberation process are a waste of time, a multiple sclerosis patient says. “As far as I know, Phase 1 and Phase 2 doesn’t include the actual procedure,” said Yvonne Anderson of the Onslow area, who travelled [Read More]

‘Liberation’ clinical trial moving ahead

‘Liberation’ clinical trial moving ahead

The federal government has announced the next step in its plan to test the so-called “liberation” treatment for multiple sclerosis, while the provincial health minister said Saskatchewan is willing to participate in that project as well as forge ahead with its [Read More]

Ottawa seeks research proposals to study MS treatment

Ottawa seeks research proposals to study MS treatment

The federal government announced Friday it is ready to accept proposals from researchers who want to study an experimental treatment for people with multiple sclerosis. Health Minister Leona Aglukkaq announced the call for proposals to study the so-called liberation therapy [Read More]

 Page 1 of 3  1  2  3 »

Latest Topics

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug

Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]